Tachycardia-induced cardiomyopathy
Authors:
K. Linhartová; L. Riedlbauchová
Authors‘ workplace:
Kardiologická klinika 2. LF UK a FN Motol, Praha
Published in:
Kardiol Rev Int Med 2011, 13(4): 225-227
Overview
Tachycardia-induced cardiomyopathy appears to be a possibly not very rare clinical event, characterised by a reversible disorder of the systolic function of the ventricles with signs of cardiac failure based on chronic or even intermittent tachyarrythmia. In the therapeutic approach, a key role is played, alongside the treatment of cardiac failure, by the normalisation, or at least adequate control of cardiac rhythm, preferably by non-pharmacological treatment, which leads to restoration of the systolic function of the ventricles, generally within weeks.
Keywords:
cardiomyopathy – supraventricular tachyarrhythmias – radiofrequential ablation
Sources
1. Riedlbauchová L. Kardiomyopatie indukovaná tachykardií. In: Veselka J, Linhartová K, Zemánek D et al (eds). Kardiomyopatie. Praha: Galén 2009: 139–143.
2. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Review. Am J Med 2003; 114: 51–55.
3. Shinbane JS, Wood MA, Jensen DN et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997; 29: 709–715.
4. Lishmanov A, Chockalingam P, Senthilkumar A et al. Tachycardia-Induced Cardiomyopathy: Evaluation and Therapeutic Options. Congest Heart Fail 2010; 16: 122–126.
5. Khasnis A, Jongnarangsin K, Abela G et al. Tachycardia-induced cardiomyopathy: a review of literature. Pacing Clin Electrophysiol 2005; 28: 710–721.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2011 Issue 4
Most read in this issue
- There’s no hypertrophy like hypertrophy, or don’t forget amyloidosis
- Pericardial calcification
- Peripartum cardiomyopathy
- Non-sarcomeric hypertrophic cardiomyopathies in adults